La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Elicio Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Elicio Therapeutics..

Elicio Therapeutics (NASDAQ:ELTX) Azioni, Catena delle Opzioni

ELICIO THERAPEUTICS INC

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics Inc

News

Management

Press Releases

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Earnings

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Financing

Elicio Therapeutics Secures $10 Million in Financing

General

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

Health Care

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

ELTX

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Anixa Biosciences

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

C4 Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Cardiff Oncology

Citius Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Fate Therapeutics

Forte Biosciences

Genelux

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Nkarta

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

AVITA Medical

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

HC Wainwright & Co.

Jones Trading

Screenshot 2024-06-07 at 5.22.00 PM

Biotech

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

Screenshot 2024-04-10 at 5.39.01 PM

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

Screenshot 2024-04-04 at 5.26.54 PM

Unlocking The Power Of Immunotherapy: Elicio Therapeutics&#39; (NASDAQ: ELTX) Novel AMP Platform

Comments

Elicio Therapeutics

Elicio Therapeutics (ELTX) Opzioni

Elicio Therapeutics (NASDAQ:ELTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO